The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
congratulations to Creo - another true milestone to widespread commercialisation
First clinical use of new Creo GI product. This is great news.
Good to see another product approved and the company poised for commercialisation. SP has drifted substantially, but things still happening behind the scenes.
One plausible reason for the dip is that investors in the sector are focusing on COVID-19 stocks. Another factor is that new devices like CREO's require extensive hands-on demonstration and evaluation which lockdown restrictions make difficult. Hopefully positive earlier exercises may have generated considerable potential for adoption by demonstrating improved outcomes for patients, doctors and bean-counters, but realistically there is probably a lot more sales work to do.
Topped up this morning following Chairman's buy and acquistion as I really think this company has reached a tipping point with numerous positive developments this year and hopefully more to come. However my buy is shown as a sell due to large spread quoted. Everything above 205 is a buy in my opinion but they are all shown as sells because they are below the midway point of the spread (202/210). Perhaps MMs trying to persuade the weak to sell by making it look everybody is selling when this is not the case.
Gla, CY
Charles Spicer, Chairman of Creo, today purchased 24,509 ordinary shares of £0.001 each in the capital of the Company ('Ordinary Shares') via his Self-Invested Personal Pension ('SIPP') at a price of 204 pence per Ordinary Share.
This is good news: Acquisition of Albyn Medical S.L.
Supplier of specialist healthcare products adds European commercial platform to Creo
not invested here but just come across this,https://www.gov.uk/government/news/welsh-secretary-visits-company-developing-covid-19-beating-technology
What a strange RNS from the perspective that it misses on the key information you’d expect to see when reporting a material new loan - repayment terms, interest rate and covenants.
Given the equity raise last year, can’t see how this is required now. Potentially gives a faster route to market with contacts and their support. I can only see this as positive given the additional due diligence over the product by the CCR - and perhaps indicates that going forward any capital requirements may be fulfilled by the board by the debt market (cheap) as opposed to equity markets.
"Creo Medical has been boosted with simultaneous CE marking status for five new devices in the field of surgical endoscopy, in a development described by its chief executive as an “amazing milestone.”"
https://www.business-live.co.uk/enterprise/creo-medical-poised-growth-after-18423629
Is going to save the NHS millions in a very short space of time,and also make a major contribution to the coffers of Creo.
All good here....buy now or hold. Good news coming.
Chris Han**** (Creo Medical founder and Chief Technology Officer), has been shortlisted for the Institution of Engineering and Technology's A F Harvey Engineering Research Prize. Prize winner will be chosen from a shortlist of five in December. Prize fund of £350,000 will be awarded to support further research led by the recipient:
https://www.lse.co.uk/rns/CREO/iet-prize-nomination-i4d7yravpuxpe3s.html
"Health economic data analysed from a cohort of UK patient cases is estimated to have saved in excess of £400,000 of NHS funding in just one hospital."
https://www.lse.co.uk/rns/CREO/positive-nhs-health-economics-data-bu331frjhp2r6kb.html
One new share for every 33 currently held at 180p per share.
Not looking very attractive following the much larger placing at 180p, which has pushed the sp down to that level (180p Bid - 185p Ask).
Positives - No dealing charge, and the chance to apply for more than your allocation.
Negative - It will raise my average if I subscribe.
Bit cautious since I saw what happened to KIER's RI a year ago.
So that's an undecided from me.
This listed 3 years ago so anything in the prospectus would probably be a bit out of date. Not sure if you subscribe to research tree but there are some quite good reports on there with forecasts from Cenkos- pretty sure you can do a month free trial.
Hi all, first time investing in Creo now. I understand the product and field, plus I like the management back story and roll out progress to plan (always nice to see).
Has anyone seen any type of financial forecast, all I can find is the market valuation for the product - which doesn't seem correct ($1bn, but I assume its for their speedboat only). I can also see they can make up to 4,000 units from their current facilities before needing some capex. I'm trying to figure out what there turnover and earnings forecast could look like over the next 3 years. Was anything in the prospectus?
Better late than never. Only a matter of time before a big US medtech swallows this up surely?
Update out.
Imminent ? ... Should have been by now.
Update on US rollout due by end of the year.
Was that a joke?
"Both agreements require the respective distributors to purchase a minimum quantity of CROMA advance energy platforms and Speedboat products during the initial period, with the first products already having been shipped to Benelux."
£260m market cap. No sales ever! Looks an E&P company valuation from the good old days :)) or Ocado :)) today!
I'm no surgeon but the feedback they get from the guys using the product is fantastic. Seems like a real game changing innovation for this type of surgery - well done Creo.
Big rise today on news that our products can be used from both ends.